GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integer Holdings Corp (NYSE:ITGR) » Definitions » Debt-to-EBITDA
中文

Integer Holdings (Integer Holdings) Debt-to-EBITDA

: 3.82 (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Integer Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11 Mil. Integer Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,043 Mil. Integer Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $276 Mil. Integer Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 3.82.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Integer Holdings's Debt-to-EBITDA or its related term are showing as below:

ITGR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.58   Med: 4.14   Max: 27.45
Current: 4.11

During the past 13 years, the highest Debt-to-EBITDA Ratio of Integer Holdings was 27.45. The lowest was 1.58. And the median was 4.14.

ITGR's Debt-to-EBITDA is ranked worse than
83.02% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs ITGR: 4.11

Integer Holdings Debt-to-EBITDA Historical Data

The historical data trend for Integer Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integer Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.65 3.82 4.23 4.91 4.04

Integer Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 5.12 4.04 3.70 3.82

Competitive Comparison

For the Medical Devices subindustry, Integer Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integer Holdings Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Integer Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Integer Holdings's Debt-to-EBITDA falls into.



Integer Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Integer Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.586 + 1042.652) / 260.767
=4.04

Integer Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.586 + 1042.652) / 276.02
=3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Integer Holdings  (NYSE:ITGR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Integer Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Integer Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Integer Holdings (Integer Holdings) Business Description

Traded in Other Exchanges
Address
5830 Granite Parkway, Suite 1150, Plano, TX, USA, 75024
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.
Executives
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Jean M. Hobby director 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jim Stephens officer: President, CRM & Neuro 5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Diron Smith officer: VP, Interim CFO 5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Joseph W Dziedzic director 1801 BAYBERRY COURT, RICHMOND VA 23226
Pamela G Bailey director 1200 G ST NW, STE 400, WASHINGTON DC 20005-3814
Jennifer M Bolt officer: President, Electrochem 10000 WEHRLE DRIVE, CLARENCE NY 14031
Carter Houghton officer: President, Electrochem 10000 WEHRLE DRIVE, CLARENCE NY 14031
Andrew Senn officer: SVP, Strategy and Business Dev 5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Marshall Mcalister C Ii officer: SVP, Gen Counsel & Secretary 1801 BAYBERRY COURT, P.O. BOX 18100, RICHMOND VA 23226
Margaret Carthy officer: SVP, Quality & Regulatory Affa 5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Joseph F Flanagan officer: EVP, Quality & Regulatory Affa 10000 WEHRLE DRIVE, CLARENCE NY 14031
Bill R Sanford director 2617 BULRUSH LANE, NAPLES FL 34105
Anthony W Borowicz officer: SVP Strategy,Corp Dev., IR 10000 WEHRLE DRIVE, CLARENCE NY 14031
Sheila Antrum director 5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024